Sandoz Group AG (SDZ.SW)
Sandoz Group AG (SDZ.SW) Stock Price, Analysis & Data
| Bid | 72.6 |
| Market Cap | 31.42B |
| Revenue (ttm) | 11.68B |
| Net Income (ttm) | 646M |
| Beta | 0.49 |
| EPS (ttm) | 1.19 |
| PE Ratio (ttm) | 61.03 |
| Forward PE | 19.59 |
| P/B (ttm) | 4.13 |
| P/S (ttm) | 2.69 |
| Earnings Date | Feb 17, 2027 |
| Ask | 72.62 |
| Volume | 89,115 |
| Avg. Volume (20D) | 727,029 |
| Open | 72.50 |
| Previous Close | 72.64 |
| Day's Range | 72.18 - 73.32 |
| 52-Week Range | 43.86 - 74.72 |
| Analyst | Buy |
| Price Target | 73.5 (1.21%) |
| Dividends | $0.8 (1.11%) |
| Ex-Dividend Date | Apr 13, 2026 |
About SDZ.SW
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage...
Financial Performance
In 2025, Sandoz's revenue was 11.16B, an increase of 7.44% compared to the previous year's 10.38B. Earnings were 914M, an increase of undefined%.
Financial numbers in CHF Financial StatementsAnalyst Forecast
According to 16 analyst ratings, the average rating for SDZ.SW stock is "Buy". The 12-month stock price forecast is 73.5, which is upside of 1.21% from the latest price.
Stock ForecastsAnalysts project revenue of ... Upgrade
1 week ago · The Wall Street Journal
Sandoz in Talks With U.S. Government About Potential Investment, CEO SaysSandoz Group is in talks with the U.S. government about manufacturing investments in the country and doesn’t see President Trump’s planned tariffs on generic medicines as a major threat, the drugmaker...
1 week ago · New Hampshire Union Leader, Manchester
NH joins $469M multistate settlement with generic drug maker Sandoz over price-fixing claimsThe New Hampshire Attorney General's Office announced a $469 million tentative agreement with generic drug manufacturer Sandoz, resolving claims that the company took part in a long-running conspiracy...